Subcutaneous Immunoglobulin Market Size, Share & Trends Analysis Report, By Type (IgG, IgA, and IgM), By End-use (Hospitals, Homecare, Clinics, Others), By Application (Immunodeficiency disease and Secondary immunodeficiency disease) and By Region, And Segment Forecasts, Till : 2030

Report ID : AMR1004981 | Industries : Healthcare | Published On :January 2024 | Page Count : 202

Subcutaneous Immunoglobulin Market Size, Share & Trends Analysis Report, By Type (IgG, IgA, and IgM), By End-use (Hospitals, Homecare, Clinics, Others), By Application (Immunodeficiency disease and Secondary immunodeficiency disease) and By Region, And Segment Forecasts, Till – 2030

Market Overview

According to Analytical Market Research, the global Subcutaneous Immunoglobulin market estimated at USD 10.34 billion in 2022 and which expected at a compound annual growth rate (CAGR) of 8.60% from 2023 to 2030. Key players in the Subcutaneous Immunoglobulin market employ various strategies to maintain and enhance their market presence. These strategies help key players capture a significant market share and remain competitive in the dynamic Subcutaneous Immunoglobulin market. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated includes proficient analysis, predictive analysis, prescriptive analysis, cumulative analysis, and value chain analysis.

SUBCUTANEOUS IMMUNOGLOBULIN MARKET DYNAMICS: KEY DRIVERS & RESTRAINTS

Increasing Incidence of Immunodeficiency Disorders
The rising prevalence of immunodeficiency disorders globally is a key driver for the growth of the subcutaneous immunoglobulin market. Immunodeficiency disorders compromise the immune system's ability to defend against infections, creating a demand for immunoglobulin replacement therapies delivered subcutaneously. As awareness increases and diagnostic capabilities improve, more patients are diagnosed, leading to a higher demand for subcutaneous immunoglobulin products.
High Cost of Treatment
The high cost associated with subcutaneous immunoglobulin therapy acts as a significant restraint for market growth. The expenses related to manufacturing, purification, and delivery systems contribute to the overall treatment cost. Affordability and reimbursement challenges in certain regions limit patient access to subcutaneous immunoglobulin therapy, impacting its adoption and hindering market expansion.

How are Segments Performing in the Global Subcutaneous Immunoglobulin Market?

Subcutaneous Immunoglobulin Type Segment Breakdown
According to Analytical Market Research, the Subcutaneous Immunoglobulin market by type is segmented into IgG, IgA, and IgM.
Subcutaneous Immunoglobulin End-use Segment Breakdown
According to Analytical Market Research, based on End-use, the market is segmented into Hospitals, Homecare, Clinics, Others.
Subcutaneous Immunoglobulin Application Segment Breakdown
According to Analytical Market Research, based on Application Type the market is segmented into immunodeficiency disease and secondary immunodeficiency disease.
Subcutaneous Immunoglobulin Geographic Exploration
According to Analytical Market Research, the North America region is predicted to dominate the market, owing to the rise in the automotive industry in the region. Other regions competing in the market are North America, Europe, Middle East and Africa and Latin America respectively.

COMPETITIVE LANDSCAPE & RECENT DEVELOPMENT: Subcutaneous Immunoglobulin

The significant players rapidly evolve with new strategies to attain a competitive edge and capture significant market share.
• For Instance, in April 2023, The U.S. FDA approved Takedas's HYQVIA to treat primary immunodeficiency in children 2 to 16 years old. It is anticipated that this endeavor will improve the company's subcutaneous immunoglobulin products.

Noticeable Players Functioning in The Global Subcutaneous Immunoglobulin Market Include:

• Johnson & Johnson (Omrix Biopharmaceuticals Inc.)
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Grifols SA
• Kedrion S.p.A
• CSL Behrin
• Biotest AG
• Octapharma AG
• ADMA Biologics, Inc.
• Shanghai RAAS Blood Products Co. Ltd..

KEY BREAKDOWN: Subcutaneous Immunoglobulin Market

By Type:
• IgG
• IgA
• IgM
By Application:
• Immunodeficiency disease
• Secondary immunodeficiency disease
By End-use:
• Hospitals
• Homecare
• Clinics
• Others.
Geographical Exploration:
• North America
o The USA
o Canada
o Mexico
• Europe
o Germany
o France
o U.K.
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Middle East and Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest of Middle East & Africa

1. Research Methodology
1.1. Global Subcutaneous Immunoglobulin Market Snapshot, 2023 and 2030
1.2. Data Mining
1.3. Validation
1.4. Primary Interviews
1.5. List of Data Sources
1.6. Future Market Projections
1.7. Industry Developments and Key Market Events
2. Executive Summary
3. Market Overview
3.1. Market Scope and Definition
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunity
3.2.4. Challenges
3.2.5. Cumulative Impact due to Recent Energy Crisis
3.2.6. Cumulative Impact due to Nearing Economic Downturn
3.2.7. Post Covid-19 World Supply & Demand Conditions
3.2.8. Cumulative Impact of Russia-Ukraine Conflict
3.2.9. Key Trends
3.3. Subcutaneous Immunoglobulin Market: Value Chain
3.3.1. List of Raw Material Supplier
3.3.2. List of Manufacturers
3.3.3. List of Applications
3.4. Porter Five Force’s Analysis
3.5. Regulatory and Technology Landscape
4. Global Subcutaneous Immunoglobulin Market Outlook: Forecast (2023 – 2030)
4.1. Key Highlights
4.1.1. Market Size and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Current Market Size Forecast, 2023–2030
4.3. Global Subcutaneous Immunoglobulin Market Outlook: Type
4.3.1. Introduction / Key Findings
4.3.2. Market Size (US$ Mn) and Forecast Type, 2023 – 2030
4.3.2.1. IgG
4.3.2.2. IgA
4.3.2.3. IgM
4.4. Global Subcutaneous Immunoglobulin Market Outlook: Application
4.4.1. Introduction / Key Findings
4.4.2. Market Size (US$ Mn) and Forecast By Application, 2023 – 2030
4.4.2.1. Immunodeficiency disease
4.4.2.2. Secondary immunodeficiency disease
4.5. Global Subcutaneous Immunoglobulin Market Outlook: End-use
4.5.1. Introduction / Key Findings
4.5.2. Market Size (US$ Mn) and Forecast By End-use, 2023 – 2030
4.5.2.1. Hospitals
4.5.2.2. Homecare
4.5.2.3. Clinics
4.5.2.4. Others
5. Global Subcutaneous Immunoglobulin Market Outlook: Region
5.1. Key Highlights
5.2. Market Size (US$ Mn) and Forecast By Region, 2023 – 2030
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Latin America
5.2.5. Middle East & Africa (MEA)
6. North America Subcutaneous Immunoglobulin Market Outlook: Forecast (2023 – 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2022
6.3.1. By Country
6.3.2. By Type
6.3.3. By Application
6.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
6.4.1. U.S.
6.4.2. Canada
6.4.3. Mexico
6.5. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
6.5.1. IgG
6.5.2. IgA
6.5.3. IgM
6.6. Market Size (US$ Mn) and Forecast By Application, 2023 – 2030
6.6.1. Immunodeficiency disease
6.6.2. Secondary immunodeficiency disease
6.7. Market Size (US$ Mn) and Forecast By End-use, 2023 – 2030
6.7.1. Hospitals
6.7.2. Homecare
6.7.3. Clinics
6.7.4. Others
7. Europe Subcutaneous Immunoglobulin Market Outlook: Forecast (2023 – 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
7.3.1. By Country
7.3.2. By Type
7.3.3. By Application
7.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Russia
7.4.5. Italy
7.4.6. Spain
7.4.7. Rest of Europe
7.5. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
7.5.1. IgG
7.5.2. IgA
7.5.3. IgM
7.6. Market Size (US$ Mn) and Forecast By Application, 2023 – 2030
7.6.1. Immunodeficiency disease
7.6.2. Secondary immunodeficiency disease
7.7. Market Size (US$ Mn) and Forecast By End-use, 2023 – 2030
7.7.1. Hospitals
7.7.2. Homecare
7.7.3. Clinics
7.7.4. Others
8. Asia Pacific Subcutaneous Immunoglobulin Market Outlook: Forecast (2023 – 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
8.3.1. By Country
8.3.2. By Type
8.3.3. By Application
8.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. South Korea
8.4.5. Australia
8.4.6. New Zealand
8.4.7. Singapore
8.4.8. Malaysia
8.4.9. Rest of Asia
8.5. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
8.5.1. IgG
8.5.2. IgA
8.5.3. IgM
8.6. Market Size (US$ Mn) and Forecast By Application, 2023 – 2030
8.6.1. Immunodeficiency disease
8.6.2. Secondary immunodeficiency disease
8.7. Market Size (US$ Mn) and Forecast By End-use, 2023 – 2030
8.7.1. Hospitals
8.7.2. Homecare
8.7.3. Clinics
8.7.4. Others
9. Latin America Subcutaneous Immunoglobulin Market Outlook: Forecast (2023 – 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
9.3.1. By Country
9.3.2. By Type
9.3.3. By Application
9.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Colombia
9.4.4. Peru
9.4.5. Chile
9.4.6. Venezuela
9.4.7. Rest of Latin America
9.5. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
9.5.1. IgG
9.5.2. IgA
9.5.3. IgM
9.6. Market Size (US$ Mn) and Forecast By Application, 2023 – 2030
9.6.1. Immunodeficiency disease
9.6.2. Secondary immunodeficiency disease
9.7. Market Size (US$ Mn) and Forecast By End-use, 2023 – 2030
9.7.1. Hospitals
9.7.2. Homecare
9.7.3. Clinics
9.7.4. Others
10. Middle East & Africa Subcutaneous Immunoglobulin Market Outlook: Forecast (2023 – 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2023 – 2030
10.3.1. By Country
10.3.2. By Type
10.3.3. By Application
10.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
10.4.1. Saudi Arabia
10.4.2. UAE
10.4.3. Egypt
10.4.4. Kuwait
10.4.5. South Africa
10.4.6. Rest of Middle East & Africa
10.5. Market Size (US$ Mn) and Forecast By Type, 2023 – 2030
10.5.1. IgG
10.5.2. IgA
10.5.3. IgM
10.6. Market Size (US$ Mn) and Forecast By Application, 2023 – 2030
10.6.1. Immunodeficiency disease
10.6.2. Secondary immunodeficiency disease
10.7. Market Size (US$ Mn) and Forecast By End-use, 2023 – 2030
10.7.1. Hospitals
10.7.2. Homecare
10.7.3. Clinics
10.7.4. Others
11. Competition Analysis
11.1. Market Share Analysis Of Top Vendors
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Key Development Strategies
11.3. Company Profiles
11.3.1. Baxter International Inc
11.3.1.1. Overview
11.3.1.2. Offerings
11.3.1.3. Business Segment & Geographic Overview
11.3.1.4. Key Financials
11.3.1.5. Key Market Developments
11.3.1.6. Key Market Strategy
11.3.2. Johnson & Johnson (Omrix Biopharmaceuticals Inc.)
11.3.3. Pfizer Inc.
11.3.4. Takeda Pharmaceutical Company Limited
11.3.5. Grifols SA
11.3.6. Kedrion S.p.A
11.3.7. CSL Behrin
11.3.8. Biotest AG
11.3.9. Octapharma AG
11.3.10. ADMA Biologics, Inc.
11.3.11. Shanghai RAAS Blood Products Co. Ltd.